Fertility and Sterility
Volume 94, Issue 5 , Pages 1753-1756, October 2010

A decade of experience emphasizes that testing for Y microdeletions is essential in American men with azoospermia and severe oligozoospermia

Presented at 2008 meeting of the American Society for Reproductive Medicine, San Francisco, CA, November 8–12, 2008.

  • Peter J. Stahl, M.D.

      Affiliations

    • Department of Urology, Weill Cornell Medical College, New York, New York
  • ,
  • Puneet Masson, M.D.

      Affiliations

    • Department of Urology, Weill Cornell Medical College, New York, New York
  • ,
  • Anna Mielnik, M.S.

      Affiliations

    • Population Council, The Rockefeller University, New York, New York
  • ,
  • Michael B. Marean, M.D.

      Affiliations

    • Department of Urology, Weill Cornell Medical College, New York, New York
  • ,
  • Peter N. Schlegel, M.D.

      Affiliations

    • Department of Urology, Weill Cornell Medical College, New York, New York
    • Population Council, The Rockefeller University, New York, New York
  • ,
  • Darius A. Paduch, M.D., Ph.D.

      Affiliations

    • Department of Urology, Weill Cornell Medical College, New York, New York
    • Population Council, The Rockefeller University, New York, New York
    • Corresponding Author InformationReprint requests: Darius A. Paduch, M.D., Ph.D., Weill Cornell Medical College, Urology, Starr 900, 525 East 68 Street, New York, NY 10065 (FAX: 212 746 7287).

Received 4 June 2009; received in revised form 31 July 2009; accepted 8 September 2009. published online 06 November 2009.

Objective

To evaluate the benefit of Y microdeletion testing.

Design

Retrospective analysis.

Setting

University-based male fertility clinic and genetics laboratory.

Patient(s)

A total of 1,591 men with sperm concentrations less than 5 million sperm/mL.

Intervention(s)

Semen analysis, Y microdeletion testing, microdissection testicular sperm extraction (TESE).

Main Outcome Measure(s)

Sperm concentration, incidence and nature of Y microdeletions, microdissection TESE outcome.

Result(s)

We identified 149 microdeletions (9.4%). 10.4% of azoospermic men and 10.1% of men with sperm concentrations >0–1 million sperm/mL harbored microdeletions. Two-thirds of microdeletions in azoospermic men were AZFa, AZFb, AZFb+c, or complete Yq deletions. Virtually all microdeletions in oligozoospermic patients were AZFc deletions. Seven hundred eighteen patients underwent microdissection TESE, including 41 with microdeletions. Microdissection TESE failed in all patients with AZFa, AZFb, AZFb+c, and complete Yq deletions. Sperm were retrieved in 15/21 AZFc deleted patients (71.4%). The presence of an AZFc deletion was associated with increased likelihood of sperm retrieval when compared with the 48.8% retrieval rate in 385 idiopathically azoospermic men who consecutively underwent microdissection TESE at our institution during the study period. Clinical pregnancy was achieved in 10/15 azoospermic AZFc deleted patients for whom sperm were successfully retrieved.

Conclusion(s)

Of azoospermic and severely oligozoospermic American men, 10% harbor Y microdeletions that alter prognosis for surgical sperm retrieval and are vertically transmissible. Y microdeletion testing is essential for genetic and preoperative counseling in these patients.

Key Words: Male infertility, azoospermia, oligozoospermia, Y microdeletions, testicular sperm extraction, sperm retrieval, Y chromosome, genetic testing

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 P.J.S. has nothing to disclose. P.M. has nothing to disclose. A.M. has nothing to disclose. M.B.M. has nothing to disclose. P.N.S. has nothing to disclose. D.A.P. has nothing to disclose.

PII: S0015-0282(09)03685-1

doi:10.1016/j.fertnstert.2009.09.006

Fertility and Sterility
Volume 94, Issue 5 , Pages 1753-1756, October 2010